Save the date: IRLAB holds Capital Markets Day on October 17, 2023

September 11, 2023

Gothenburg, Sweden, September 11, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a Capital Markets Day on October 17, 2023. The Capital Markets Day will provide an opportunity for investors, analysts, and financial media to get an update on IRLAB’s development portfolio and operations as well as its growth strategy. The program will include presentations by the IRLAB’s executive team as well as key external speakers.

[mfn_before_post]

Gothenburg, Sweden, September 11, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a Capital Markets Day on October 17, 2023. The Capital Markets Day will provide an opportunity for investors, analysts, and financial media to get an update on IRLAB’s development portfolio and operations as well as its growth strategy. The program will include presentations by the IRLAB’s executive team as well as key external speakers.

IRLAB’s Capital Markets Day will be held in central Stockholm, Sweden.

More information and a link for registration will be communicated in due course.

For more information

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

Save the date: IRLAB holds Capital Markets Day on October 17, 2023

[mfn_after_post]

Documents & Links